Product
SGLT2 inhibitor
Aliases
dapagliflozin, ertugliflozin
27 clinical trials
35 indications
Indication
Healthy AdultIndication
Type 2 Diabetes MellitusIndication
Atrial FibrillationIndication
Congestive Heart FailureIndication
Volume OverloadIndication
KetonesIndication
MetabolismIndication
Heart AttackIndication
Diabetes MellitusIndication
Type 1Indication
Preserved Ejection FractionIndication
Type 2 DiabetesIndication
Diabetic NephropathyIndication
Perioperative ComplicationIndication
Fatty LiverIndication
NonalcoholicIndication
AscitesIndication
CirrhosisIndication
LiverIndication
Type 2Indication
Rheumatic Heart DiseaseIndication
Drug-induced Platelet DysfunctionIndication
Acute Heart FailureIndication
Ventilator-associated pneumoniaIndication
Chronic Kidney DiseaseIndication
ChronicIndication
DiabetesIndication
COVID-19Indication
Atherosclerotic Cardiovascular DiseaseIndication
Myocardial InfarctionIndication
Cellular SenescenceIndication
SGLT2 InhibitorsIndication
Ventricular RemodelingIndication
Ventricular DysfunctionClinical trial
A Randomized, Open-label, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of JLP-2008 and the Co-admin. of JT-001, and JT-002 for Healthy Subjects in Fasted StateStatus: Completed, Estimated PCD: 2022-06-13
Clinical trial
A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s)Status: Completed, Estimated PCD: 2023-10-20
Clinical trial
Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic SurgeryStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Alfapump® DSR Feasibility Study in Subjects With Persistent Congestion Due to Heart Failure, Resistant to Loop Diuretic TreatmentStatus: Active (not recruiting), Estimated PCD: 2022-08-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients With Type 2 Diabetes MellitusStatus: Not yet recruiting, Estimated PCD: 2024-03-01
Clinical trial
Role of SGLT2I in Diabetic Patients With Myocardial InfarctionStatus: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers (CASINO)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin DeficiencyStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
The Efficacy of Enavogliflozin on Exercise Performance and Diastolic Function in Heart Failure With Preserved Ejection Fraction: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Short Term Outcome of SGLT2 Inhibitors on Patients Who Undergo Cardiac Surgery in Perioperative PeriodStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label TrialStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
The Impact Of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes MellitusStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
Efficacy and Safety of Incorporating Sodium-glucose Cotransporter-2 Inhibitors to Regimens of Diabetes Patients Already Receiving TherapyStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Potential Role of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Ascites in Cirrhotic PatientsStatus: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Effect of Gliflozins on Heart Failure Due to Regurgitant Rheumatic Valve DiseaseStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.Status: Completed, Estimated PCD: 2021-12-31
Clinical trial
The Potential Beneficial Effects of SGLT2 Inhibitors in Patients With Acute Decompensated Heart Failure During Ventilator Weaning: a Prospective Multicenter Cohort Study.Status: Recruiting, Estimated PCD: 2030-10-09
Clinical trial
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19Status: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesStatus: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
Peri-tREatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index Measured by Cardiac maGnetic rEsonance Imaging in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary InterventionStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 DiabetesStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Complementary Effects of New Diabetes Medications on Adrenal Function and Intestinal MicrobiotaStatus: Completed, Estimated PCD: 2023-01-23
Clinical trial
Evaluation of the Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Combined Therapy in Patients With HFrEF: an Echocardiographic Study.Status: Recruiting, Estimated PCD: 2024-12-31